Search
Paclitaxel Treatment Options in Illinois
A collection of 564 research studies where Paclitaxel is the interventional treatment. These studies are located in the Illinois, United States. Paclitaxel is used for conditions such as Breast Cancer, Ovarian Cancer and Non-Small Cell Lung Cancer.
385 - 396 of 564
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Radiation Therapy Combined With Paclitaxel and Carboplatin in Treating Patients With Stage III Non-Small Cell Lung Cancer
Completed
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving them with specialized radiation therapy may kill more tumor cells.
PURPOSE: This phase I/II trial is studying the effectiveness of radiation therapy combined with paclitaxel and carboplatin in treating patients who have stage III non... Read More
Gender:
ALL
Ages:
All
Trial Updated:
11/27/2017
Locations: Saint Anthony's Hospital at Saint Anthony's Health Center, Alton, Illinois +2 locations
Conditions: Lung Cancer
Study of Pazopanib and Paclitaxel in Advanced Non-small Cell Lung Cancer
Completed
The Phase I part of the study will identify the doses of pazopanib and paclitaxel that can be administered safely in combination. The Phase II part of the study will not be progressed as documented in Protocol Amendment 01.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/08/2017
Locations: GSK Investigational Site, Chicago, Illinois
Conditions: Lung Cancer, Non-Small Cell
Bortezomib, Paclitaxel, Carboplatin and Radiation Therapy for Non-Small Cell Lung Cancer
Completed
This phase I/II trial (phase I closed to accrual as of 09/29/2009) is studying the side effects and best dose of bortezomib, paclitaxel, and carboplatin when given with radiation therapy and to see how well they work in treating patients with stage IIIA or stage IIIB non-small cell lung cancer that cannot be removed by surgery. Bortezomib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/02/2017
Locations: Rush - Copley Medical Center, Aurora, Illinois +45 locations
Conditions: Recurrent Non-small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
A Pharmacokinetic Study of AMG 386 in Cancer Subjects With Normal and Impaired Renal Function
Completed
This is a phase 1, open-label pharmacokinetic study where up to 40 subjects with advanced solid tumors (up to 6-10 with normal renal function and up to 18-30 with varying degrees of renal dysfunction) will receive weekly doses of AMG 386 intravenously. The primary objective is to evaluate the pharmacokinetics (PK) of single agent AMG 386 in subjects with various degrees of renal function. Once the AMG 386 PK characterization is complete in the first 5 weeks of the study, all subjects will be all... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/01/2017
Locations: Research Site, Chicago, Illinois
Conditions: Advanced Solid Tumors, Kidney Disease, Renal Impairment
Abraxane With or Without Tigatuzumab in Patients With Metastatic, Triple Negative Breast Cancer
Completed
Breast cancer is the most commonly diagnosed cancer and the second leading cause of cancer deaths in American women. Metastatic disease including metastatic breast cancer unfortunately remains incurable. One reason is due to the inability to develop specific therapies for specific cancer subsets.
The use of modern genomic techniques has significantly enhanced our recent understanding of breast cancer biology. Five distinct breast cancer subsets have been recognized, one of which is basal-like b... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/24/2017
Locations: University of Chicago, Chicago, Illinois
Conditions: Breast Cancer, Triple Negative Breast Cancer, Stage IV Breast Cancer, Metastatic Breast Cancer
Treatment Extension Study for Patients Who Have Previously Participated and Have Benefited From Iniparib in a Clinical Trial
Completed
The purpose of this study is to assess the safety and tolerability of iniparib administered as monotherapy or in combination regimens in patients previously treated with iniparib in a clinical study and who have derived clinical benefit after completion of the parental study's objectives.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/12/2017
Locations: Investigational Site Number 840039, Maywood, Illinois
Conditions: Solid Tumors
Intraperitoneal Paclitaxel, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Stage III-IV Endometrial Cancer
Completed
This phase I trial studies the side effects and best dose of intraperitoneal paclitaxel when given together with doxorubicin hydrochloride and cisplatin in treating patients with stage III-IV endometrial cancer. Drugs used in chemotherapy, such as paclitaxel, doxorubicin hydrochloride, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) and giving them in diffe... Read More
Gender:
FEMALE
Ages:
All
Trial Updated:
08/23/2017
Locations: University of Chicago Comprehensive Cancer Center, Chicago, Illinois
Conditions: Endometrial Adenosquamous Carcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Mixed Adenocarcinoma, Endometrial Serous Adenocarcinoma, Endometrial Squamous Cell Carcinoma, Endometrial Undifferentiated Carcinoma, Recurrent Uterine Corpus Carcinoma, Stage IIIA Uterine Corpus Cancer, Stage IIIC Uterine Corpus Cancer, Stage IVA Uterine Corpus Cancer, Stage IVB Uterine Corpus Cancer
Carboplatin, Paclitaxel, and Bevacizumab in Treating Patients With Locally Recurrent or Metastatic Breast Cancer
Completed
RATIONALE: Drugs used in chemotherapy, such as carboplatin and paclitaxel albumin-stabilized nanoparticle formulation, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry cancer-killing substances to them. Bevacizumab may also stop the... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/16/2017
Locations: Good Samaritan Cancer Care Center at Advocate Good Samaritan Hospital, Downers Grove, Illinois +5 locations
Conditions: Breast Cancer
Taxane Therapy With or Without Bavituximab for the Treatment of HER2-Negative Metastatic Breast Cancer
Withdrawn
The primary purpose of this research study is to see whether adding bavituximab (an investigational drug) to the standard chemotherapy drug taxane, will improve the results of the treatment for HER2-negative metastatic breast cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/07/2017
Locations: Peregrine Pharmaceuticals Investigational Site, Tinley Park, Illinois
Conditions: Metastatic Breast Cancer
A Study of MEHD7945A in Combination With Cisplatin and 5-Fluorouracil (5-FU) or Paclitaxel and Carboplatin in Participants With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M SCCHN)
Completed
This open-label, multicenter study will evaluate the safety, tolerability, and pharmacokinetics of MEHD7945A in combination with chemotherapy (either cisplatin plus 5-FU or carboplatin plus paclitaxel) in participants with previously untreated R/M SCCHN. There are two stages for each arm in this study: a Dose-limiting Toxicity (DLT)-evaluation stage (Stage I) and a cohort-expansion stage (Stage II). In Stage I, DLTs will be assessed during a DLT Assessment Window of 21 days (i.e., Cycle 1 Day 1... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/04/2017
Locations: University of Chicago; Hematology/Oncology, Chicago, Illinois
Conditions: Head and Neck Cancer
A Study of MM-111 and Paclitaxel With Trastuzumab in Patients HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach
Terminated
To determine whether the combination of MM-111 plus paclitaxel and trastuzumab is more effective than paclitaxel and trastuzumab alone
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/19/2017
Locations: Not set, Urbana, Illinois
Conditions: HER-2 Gene Amplification, Esophagus Cancer, Gastroesophageal Junction Cancer, Stomach Cancer
A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer
Completed
This is a randomized, Phase III, open-label, multicenter study.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
06/13/2017
Locations: Mid-Illinois Hematology & Oncology, Normal, Illinois +1 locations
Conditions: Breast Cancer
385 - 396 of 564